Major strides for the company on two fronts – psychedelic therapies and treatment-resistant depression (TRD) – came in the ...

In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...

GH Research's inhaled psychedelic therapy GH001 has shown promise in a mid-stage trial in treatment-resistant depression (TRD ...

As of September 2024, GH Research had $193 million in cash but expects that by the end of December, the cash will likely be roughly $182 million. The company has an accumulated deficit of $97 million.

Now 29, Turner remembers the perspective that came to her in the months after she was crushed by that tree in Portland’s ...

The results come from a phase 2a study of BPL-003, a novel formulation of 5-MeO-DMT (sometimes called mebufotenin), which is a psychoactive compound found in a wide variety of plant species ...

在现代社会中，抑郁症已成为亟待解决的公共健康危机。每个人似乎都能体会到心灵深处的低落，不幸的是，许多人未能找到有效的解脱之路。然而，最近的一项突破性研究不禁让人惊叹：近60%的难治性抑郁症患者在仅仅8天内竟然获得了显著的缓解。

最近，GHResearch公司针对TRD患者进行了一项创新疗法的临床试验，令人瞩目的发现是，在疗法GH001的帮助下，近60%的患者在短短8天内获得了显著的症状缓解。试验结果显示，使用GH001治疗的患者，其抑郁症状在第8天时显著改善，相较于安慰剂组，其评估得分降低了15.5分，而安慰剂组则没有任何改善。借助这一创新疗法，57.5%的患者在第8天达到了临床症状缓解的标准，而这一数字在安慰剂组则为零 ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

GH ...

Cassidy Horton is a finance writer covering banking, life insurance and business loans. She has worked with top finance brands including NerdWallet, MarketWatch and Consumer Affairs. Cassidy first ...

Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of ...